The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

MLA

Rana Abdelnabi, et al. “The Combined Treatment of Molnupiravir and Favipiravir Results in a Potentiation of Antiviral Efficacy in a SARS-CoV-2 Hamster Infection Model.” EBioMedicine, vol. 72, no. 103595-, Oct. 2021. EBSCOhost, https://doi.org/10.1016/j.ebiom.2021.103595.

APA

Rana Abdelnabi, Caroline S. Foo, Suzanne J.F. Kaptein, Xin Zhang, Thuc Nguyen Dan Do, Lana Langendries, Laura Vangeel, Judith Breuer, Juanita Pang, Rachel Williams, Valentijn Vergote, Elisabeth Heylen, Pieter Leyssen, Kai Dallmeier, Lotte Coelmont, Arnab K. Chatterjee, Raf Mols, Patrick Augustijns, Steven De Jonghe, … Johan Neyts. (2021). The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine, 72(103595-). https://doi.org/10.1016/j.ebiom.2021.103595

Chicago

Rana Abdelnabi, Caroline S. Foo, Suzanne J.F. Kaptein, Xin Zhang, Thuc Nguyen Dan Do, Lana Langendries, Laura Vangeel, et al. 2021. “The Combined Treatment of Molnupiravir and Favipiravir Results in a Potentiation of Antiviral Efficacy in a SARS-CoV-2 Hamster Infection Model.” EBioMedicine 72 (103595-). doi:10.1016/j.ebiom.2021.103595.